![Artwork](/static/images/128pixel.png)
Go offline with the Player FM app!
Caitlyn Krebs | Nalu Bio - Encore
Manage episode 316726146 series 2973978
Learning from nature, delivering through chemistry.
The end of cannabis prohibition has made cannabis research possible which has generated a wave of cannabis biotech start-ups. Caitlyn Krebs the co-founder and CEO of Nalu Bio joins Ross O'Brien and Maggie Kelly from Bonaventure Equity to talk about the challenges and opportunities of being at the intersection of biotech and cannabis. As an entrepreneur with many successful exits under her belt she also shares advice for aspiring entrepreneurs.
Cannabis Capital - https://podconx.com/podcasts/cannabis-capital
Ross O'Brien - https://podconx.com/guests/ross-obrien
Maggie Kelly - https://podconx.com/guests/maggie-kelly
Bonaventure Equity - https://www.bvequity.com/
Caitlyn Krebs - https://podconx.com/guests/caitlyn-krebs
Nalu Bio - https://www.nalubio.com/
23 episodes
Manage episode 316726146 series 2973978
Learning from nature, delivering through chemistry.
The end of cannabis prohibition has made cannabis research possible which has generated a wave of cannabis biotech start-ups. Caitlyn Krebs the co-founder and CEO of Nalu Bio joins Ross O'Brien and Maggie Kelly from Bonaventure Equity to talk about the challenges and opportunities of being at the intersection of biotech and cannabis. As an entrepreneur with many successful exits under her belt she also shares advice for aspiring entrepreneurs.
Cannabis Capital - https://podconx.com/podcasts/cannabis-capital
Ross O'Brien - https://podconx.com/guests/ross-obrien
Maggie Kelly - https://podconx.com/guests/maggie-kelly
Bonaventure Equity - https://www.bvequity.com/
Caitlyn Krebs - https://podconx.com/guests/caitlyn-krebs
Nalu Bio - https://www.nalubio.com/
23 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.